Fasting insulin concentration and the insulin response to an oral glucose tolerance test were measured in 15 women with polycystic ovary syndrome (PCOS) and 6 weight-matched normal women. The fasting insulin concentrations were not increased in PCOS in comparison to normal women. Insulin response to an oral glucose test was significantly decreased (p < 0.05) in PCOS at 30 min, although 63% of these women had mild impairment of glucose tolerance. The glucose response did not differ between the obese PCOS patients and those with nonobesity. No correlations were demonstrated between the fasting serum insulin concentrations and insulin response at 30 min, and both androgens and the luteinizing hormone. These findings suggest that (1) hyperinsulinemia is not a feature of PCOS in Japan; (2) only obese PCOS patients have a tendency of abnormalities in insulin secretion; (3) it is evident that PCOS represents an inadequately characterized disorder of insulin action and a novel paradigm in which to investigate the relationship between reproductive functions and carbohydrate metabolism.

Keywords:
Polycystic ovary syndrome, Impaired glucose tolerance, Insulin
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.